These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 34238136

  • 21. Romiplostim: a review of its use in immune thrombocytopenia.
    Keating GM.
    Drugs; 2012 Feb 12; 72(3):415-35. PubMed ID: 22316355
    [Abstract] [Full Text] [Related]

  • 22. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
    Al-Samkari H, Van Cott EM, Kuter DJ.
    Ann Hematol; 2019 Mar 12; 98(3):581-588. PubMed ID: 30446804
    [Abstract] [Full Text] [Related]

  • 23. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
    Selleslag D, Bird R, Altomare I, Giagounidis A, Janssens A, Pabinger I, Pullarkat V, Wei H, Kreuzbauer G.
    Eur J Haematol; 2015 Feb 12; 94(2):169-76. PubMed ID: 25039799
    [Abstract] [Full Text] [Related]

  • 24. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
    Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R.
    Int J Hematol; 2011 Jul 12; 94(1):71-80. PubMed ID: 21706145
    [Abstract] [Full Text] [Related]

  • 25. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Tarantino MD, Despotovic J, Roy J, Grainger J, Cooper N, Beam D, Raj A, Maschan A, Kim J, Eisen M.
    Pediatr Blood Cancer; 2020 Nov 12; 67(11):e28630. PubMed ID: 32902132
    [Abstract] [Full Text] [Related]

  • 26. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
    Janssens A, Rodeghiero F, Anderson D, Chong BH, Boda Z, Pabinger I, Červinek L, Terrell DR, Wang X, Franklin J.
    Ann Hematol; 2016 Jun 12; 95(7):1077-87. PubMed ID: 27130310
    [Abstract] [Full Text] [Related]

  • 27. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP, Heddle NM, Kelton JG, Hamilton K, Wang G, Sholapur N, Carruthers J, Hsia C, Blais N, Toltl L, Hamm C, Pearson MA, Arnold DM.
    Transfusion; 2016 Jan 12; 56(1):73-9. PubMed ID: 26400824
    [Abstract] [Full Text] [Related]

  • 28. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
    Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R.
    Int J Hematol; 2012 Jun 12; 95(6):652-9. PubMed ID: 22532046
    [Abstract] [Full Text] [Related]

  • 29. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
    Sivera P, Ruella M, Gueli A, Hu H, Wade M, Tarella C.
    Blood Coagul Fibrinolysis; 2012 Jun 12; 23(4):331-4. PubMed ID: 22343685
    [Abstract] [Full Text] [Related]

  • 30. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R.
    Am J Hematol; 2016 May 12; 91(5):E293-5. PubMed ID: 26910388
    [Abstract] [Full Text] [Related]

  • 31. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M.
    Lancet; 2016 Jul 02; 388(10039):45-54. PubMed ID: 27103127
    [Abstract] [Full Text] [Related]

  • 32. Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury.
    Watanabe R, Tabayashi T, Tomikawa T, Sagawa M, Anan-Nemoto T, Kimura Y, Takahashi Y, Tokuhira M, Otaki S, Oi H, Sawano M, Sugiyama S, Kizaki M.
    Int J Hematol; 2017 Jan 02; 105(1):100-103. PubMed ID: 27709451
    [Abstract] [Full Text] [Related]

  • 33. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia.
    Kuter DJ, Tarantino MD, Lawrence T.
    Blood Rev; 2021 Sep 02; 49():100811. PubMed ID: 33781612
    [Abstract] [Full Text] [Related]

  • 34. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
    Newland A, Godeau B, Priego V, Viallard JF, López Fernández MF, Orejudos A, Eisen M.
    Br J Haematol; 2016 Jan 02; 172(2):262-73. PubMed ID: 26537623
    [Abstract] [Full Text] [Related]

  • 35. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.
    Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S.
    Br J Haematol; 2013 May 02; 161(3):411-23. PubMed ID: 23432528
    [Abstract] [Full Text] [Related]

  • 36. Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia.
    Mingot-Castellano ME, Caparrós IS, Fernández F, Perera-Alvarez MDM, Jimenez-Bárcenas R, Casaus García A, González-Silva M, Yera-Cobo M, Nieto-Hernandez MM, Rodríguez-Fernandez MJ, Díaz-Canales D.
    Blood Coagul Fibrinolysis; 2018 Jun 02; 29(4):374-380. PubMed ID: 29738335
    [Abstract] [Full Text] [Related]

  • 37. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies.
    Kuter DJ, Newland A, Chong BH, Rodeghiero F, Romero MT, Pabinger I, Chen Y, Wang K, Mehta B, Eisen M.
    Br J Haematol; 2019 May 02; 185(3):503-513. PubMed ID: 30793285
    [Abstract] [Full Text] [Related]

  • 38. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
    Newland A.
    Eur J Haematol Suppl; 2009 Mar 02; (71):20-5. PubMed ID: 19200304
    [Abstract] [Full Text] [Related]

  • 39. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K.
    Clin J Oncol Nurs; 2019 Apr 01; 23(2):212-216. PubMed ID: 30880797
    [Abstract] [Full Text] [Related]

  • 40. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
    Zhang J, Liang Y, Ai Y, Xie J, Li Y, Zheng W.
    Expert Opin Pharmacother; 2017 Oct 01; 18(15):1543-1551. PubMed ID: 28845713
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.